Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

The Interventional Pharmacoeconomic Toolbox Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Oct

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

The Interventional Pharmacoeconomic Toolbox Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Verifying the Seen and Unseen by AI in Cancer Imaging

AI-Extracted Chart Data for Expanding Surgical Oncology Learnings

Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families

Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas

Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights